Working with Funders

*Funders = any individual or organisation that contributes funding to The Migraine Trust, including companies, charitable trusts and foundations, and individual donors.

Industry = companies working in the field of health and more specifically, headache and migraine, such as pharmaceutical and medical device companies.

(Supporters = third parties that have interest in supporting our work but who do not necessarily contribute funding).

Background

The aim of The Migraine Trust is to promote research into migraine and reduce its burden on sufferers.

To further its aims, the Trust seeks funding and support from a variety of sources such as from individuals, charitable trusts and the corporate sector. Our latest annual report and accounts is available to download from our website. We are registered with the Fundraising Regulator and committed to good practice in accordance with the Fundraising Promise and the Code of Fundraising Practice, as well as the regulations and policies set by the Charity Commission and the Scottish Charity Regulator.

The Trust acts with openness, transparency and in an inclusive manner with regards to all our work with all funders and industry partners. We recognise that collaborative working with corporate partners, can significantly help to further the Trust’s aims. By working in partnership and sharing intelligence we will help to improve the lives of people with migraine.

The purpose of this policy is to ensure that in seeking and securing funding the Trust has a clearly understood way of working, underpinned by high ethical principles. In particular, the Trust will:

  • Be open and transparent
  • Act to further our charitable objects
  • Protect ourindependence and reputation
  • Treat all funders fairly and honestly
  • Act with due care and atten

Key principles of working with funders

Open and transparent

  • The Trust seeks a diverse funding base in the interests of financial sustainability and to avoid both dependence and the appearance of dependence on any one source.
  • The Trust will be open and transparent in response to any public or media enquiry regarding our collaboration with funders/industry.
  • The Trust will be open and transparent regarding our Trustees’ and staff’s relationships with the funders/industry. We will identify any conflicts of interests that arise from the activities of our Trustees and staff in relation to any collaboration the Trust has with funders/industry.
  • Once we have permission, The Trust will acknowledge significant financial contributions from funders/industry in its annual report in line with Charity Commission accounting procedures, and we will make this clear on our website.
  • The Trust will acknowledge and thank sponsors of individual projects or activities proportionately so as to avoid advertisin The Trust will consider carefully any request to display corporate logos and avoid giving them undue prominence.
  • The Trust will be open and transparent about its policy and influencing priorities, and how these are developed and pursued.
  • This policy was adopted by the Board of Trustees in October 2017.
  • It will be published on the Trust’s website and will be reviewed annua

Furthering our charitable objects

  • The Trust’s priorities and work programme are informed by the interests of patients; are determined in a collaborative effort; and are approved annually by the Board of Trustee
  • The Trust will undertake only those activities which are consistent with our agreed priorities and work progra
  • The Trust needs to recover all its costs to ensure that it can remain a viable organisa We will therefore favour unrestricted funding arrangements that support core costs, and will otherwise seek to recover the full overhead costs associated with specific activities.
  • The Trust will retain complete editorial control of the content of its plans, policies, written outputs – including research and policy materials – and the programmes for its events and mee

Protect our independence and reputation

  • The Trust welcomes financial and other material support for its work as long as funding is provided free of any conditions that might compromise the Trust’s charitable status, reputation and independence. Any support that is accepted will further the Trust’s objectives and will be judged by its potential benefit for people with migraine. The Trust will not endorse or promote products or services provided by funders, industry or other supporters, or lobby for their commercial interests, and will seek to avoid acting so as to give the appearance of favouring any commercial intere We will work alongside supporters on campaigns, lobbying and calls to action only where these align with the Trust’s own priorities and values.
  • The Trust’s name and logo are its property and may not be used by a funder without prior written agreement of the charity, and vice versa.
  • Where funding is sought for particular projects or activities the Trust prefers to engage with more than one par Exclusivity may be considered at the discretion of the Trustees.
  • The Trust will not accept funding or support from any party whose activities and business practices are demonstrably unlawful or unethica
  • The Trust will not accept funding or support from any party whose activities are demonstrably harmful to health and wellbeing, or in other ways demonstrably harmful to the public good, in the judgment of the Board of Trustee The Trust will expect funders to comply with their respective industry codes of practice governing funding relationships with third parties such as charities.
  • The Trust will on occasion use information available in the public domain to research potential funders and funding opportunities

 Treat all funders fairly and honestly

  • The Trust will, when providing information, insight or opportunities to support activities, take reasonable steps to ensure that such information is shared with all relevant parties at the same time. We will be transparent about co-funders on any given project.
  • The Trust will store all information it receives from funders securely and confidentially and not share contacts without the funders prior consent.
  • The Trust will not alter the project funding goal or timeline without advising the funder in advance.

Due care and attention

  • The Trust will accept funding from funders, industry and other parties when:
  • It believes that the funding will benefit the Trust and people affected by migraine
  • The funder agrees not to influence the Trust’s policies or activities, either explicitly or implicitly.
  • In particular, every collaboration will be assessed and agreed on an individual basis by the Chief Executive and Board of Trustees of The Trust.
  • The Trust would consider collaboration with pharmaceutical/medical device industry for clinical research. This would be decided on a case by case basis.
  • Collaboration with pharmaceutical/medical device industry for clinical research will only be conducted on the Trust’s terms and conditions. Industry will have to demonstrate that it is not possible for the research to be carried out by academic researchers.
  • All proposals to accept pharmaceutical/medical device industry support will be notified in advance to the Board of Trustees by the Chief Executive, alongside an account of the due diligence performed on the potential funder.
  • This due diligence will cover the nature, activities and reputation of the third party funder; the nature of the funding or support relationship proposed; the associated activities proposed; the size of the proposed contribution; and any risks posed to the Trust and associated m
  • Where the proposed level of funding from each individual funder equals or exceeds 10 per cent of Trust’s forecasted income in any one financial year, or is likely to have a significant impact on Trust’s workload, the Board of Trustees must formally approve the proposal, on advice from the Chief Executive, before it can procee
  • A written agreement will be drawn up at the beginning of each new partnership with a funder/industry and each partnership will be monitored and evaluated.